Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 29287.09%.

  • SAB Biotherapeutics' EBITDA Margin changed N/A to 29287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69102.73%, marking a year-over-year increase of 725254000.0%. This contributed to the annual value of 3244.87% for FY2024, which is 15443200.0% down from last year.
  • SAB Biotherapeutics' EBITDA Margin amounted to 29287.09% in Q3 2025.
  • In the past 5 years, SAB Biotherapeutics' EBITDA Margin registered a high of 29287.09% during Q3 2025, and its lowest value of 8726.26% during Q4 2024.
  • In the last 5 years, SAB Biotherapeutics' EBITDA Margin had a median value of 160.26% in 2022 and averaged 1654.83%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -74703700bps in 2023, then surged by 190017700bps in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' EBITDA Margin stood at 66.41% in 2021, then tumbled by -448bps to 363.74% in 2022, then plummeted by -1601bps to 6187.9% in 2023, then crashed by -41bps to 8726.26% in 2024, then soared by 436bps to 29287.09% in 2025.
  • Its EBITDA Margin was 29287.09% in Q3 2025, compared to 15124.81% in Q2 2025 and 15484.95% in Q1 2025.